Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
Fiscal Year: January - December
Amgen Inc. (AMGN), listed on the NASDAQ, has a market capitalization of $. As of Oct 04, 2025, the stock is trading at $297.89 per share, offering investors a clear view of its current market value. Amgen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 24.36, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Amgen Inc. also offers a dividend yield of 3.2%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Amgen Inc. (AMGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Amgen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Amgen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Amgen Inc. is 15.12, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Amgen Inc. (AMGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Amgen Inc. (AMGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Amgen Inc. (AMGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Amgen Inc.. To access the full SS Score, consider upgrading your subscription.
Amgen Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 24.36. Investors should compare these metrics with industry peers to gauge whether Amgen Inc. is outperforming or underperforming within its sector.
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK...
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
THOUSAND OAKS, Calif. , Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see ...
Despite the political noise coming out of the White House over efforts to lower drug prices, Amgen Inc.'s oncology franchise has continued to deliver strong performance since the start of 2025. So, AM...
Amgen offers a compelling value and income opportunity after a recent price dip, trading below historical valuation multiples. AMGN posted strong Q2 results with robust performance across its innovati...
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...
Amgen Inc. (NASDAQ:AMGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice Pre...
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluati...
THOUSAND OAKS, Calif. and TOKYO , Sept.
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m.
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Amgen Inc. (NASDAQ:AMGN) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capp...
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif. , Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest...
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments ...
THOUSAND OAKS, Calif. , Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m.
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to in...
Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 12.33B | 18.66% | Est @18.7% |
2026 | 14.27B | 15.72% | Analyst x5 |
2027 | 14.03B | -1.67% | Analyst x5 |
2028 | 14.35B | 2.23% | Analyst x4 |
2029 | 15.08B | 5.13% | Analyst x4 |
2030 | 15.34B | 1.69% | Est @1.7% |
2031 | 15.62B | 1.88% | Est @1.9% |
2032 | 15.94B | 2.00% | Est @2.0% |
2033 | 16.27B | 2.10% | Est @2.1% |
2034 | 16.60B | 2.02% | Est @2.0% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 7.36B | 1.00 | 7.36B |
2024A | 10.39B | 1.00 | 10.39B |
2025E | 12.33B | 1.08 | 11.43B |
2026E | 14.27B | 1.16 | 12.26B |
2027E | 14.03B | 1.26 | 11.17B |
2028E | 14.35B | 1.36 | 10.59B |
2029E | 15.08B | 1.46 | 10.31B |
2030E | 15.34B | 1.58 | 9.72B |
2031E | 15.62B | 1.70 | 9.18B |
2032E | 15.94B | 1.84 | 8.68B |
2033E | 16.27B | 1.98 | 8.21B |
2034E | 16.60B | 2.14 | 7.76B |
Terminal | 315.30B | 2.14 | 147.46B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.